Mission-first discipline.
Market-rate returns.
The highest-burden conditions are a narrow, well-documented problem space.
The conditions that consume the majority of U.S. healthcare expenditure (chronic disease, behavioral health, metabolic syndrome, maternal health) are well-documented, structurally underserved, and increasingly addressable by AI-native platforms. Seed stage is where that addressability is built. By the time a company reaches Series A, its clinical assumptions, data architecture, and outcome measurement frameworks are largely set. Investors who enter at seed do not just provide capital. They shape whether a company is built to prove what it claims. That is the window AHV is designed to occupy.
Where we invest
We invest across five verticals: cardiometabolic disease, behavioral health, maternal and pediatric health, oncology and specialty care, and the infrastructure and platform layers these depend on.
Our Approach
01 Burden-First
We prioritize conditions by morbidity burden and cost concentration before evaluating technology. Burden alone is not enough. We invest where failing to solve the problem is already expensive for a specific economic buyer, because that is what turns a clinical need into a purchase decision.
02 Responsible AI
Health AI that cannot explain its clinical reasoning, withstand regulatory scrutiny, or document its training data is a liability, not an investment.
03 Health Value
Every portfolio company is expected to articulate, from day one, how it will measure its impact on patient outcomes, total cost of care, or access to services.
Portfolio
Current holdings, warehoused ahead of Fund I.
Nest Health delivers whole-family primary care in the home to Medicaid-enrolled families.
Aikium applies artificial intelligence to map protein-protein interactions at scale for drug discovery.
Phiex Technologies has developed a sterilization technology for single-use medical devices designed to replace ethylene oxide.
Two structural decisions that are rare at seed stage
Aligned Health Ventures was built with two deliberate structural decisions that distinguish it from a typical seed-stage healthcare fund.
The first is capital structure. AHV's structure has been reviewed by outside counsel for compatibility with Program Related Investments and Mission Related Investments, making foundation capital accessible at seed stage.
The second is governance. BoardKit, a system built by AHV and deployed across every portfolio company at investment, installs the meeting cycle, board composition discipline, and documentation practice from the first check. Seed-stage companies rarely have functioning board governance, and the gap surfaces later as a diligence problem at Series A, in a strategic conversation, or in a health system commercial review. BoardKit means governance is auditable from day one rather than reconstructed under pressure.
